中生(01177.HK)逆弹逾7.5%重越10天线 季绩胜预期获瑞信看好
中国生物制药(01177.HK)首季纯利年增0.6%至8.62亿人民币与营收微升至62.22亿人民币兼维持季度息2港仙,瑞信升中生评级至「跑赢大市」及目标价升至13.2元,以反映公司季绩胜预期,上调未来三年盈测2.68%/2.7%/5.29%,相信肿瘤药业务未来增长将快过预期。该股扭两连挫,股价逆市急弹重越20天及10天线(11.92元),最高见12.38元,现造12.22元,逆弹7.6%,成交急增至1.51亿股,涉资18.33亿元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.